Thirdline antiretroviral therapy including raltegravir RAL darunavir DRVr andor etravirine ETR is well tolerated and achieves durable virologic suppression over 144 weeks in resourcelimited settings ACTG A5288 strategy trial

Simple item page
dc.citation.doi10.1002/JIA2.25905
dc.citation.epage6
dc.citation.spage1
dc.contributor.authorAnchalee Avihingsanon
dc.contributor.authorMichael D. Hughes
dc.contributor.authorRobert Salata
dc.contributor.authorCatherine Godfrey
dc.contributor.authorSharlaa Badal-Faesen
dc.contributor.authorLerato Mohapi
dc.contributor.authorE et al
dc.date.accessioned2023-10-17T10:12:25Z
dc.date.available2023-10-17T10:12:25Z
dc.identifier.citationSCOPUS
dc.identifier.issn17582652
dc.identifier.urihttps://hdl.handle.net/10539/36761
dc.journal.titleJOURNAL OF THE INTERNATIONAL AIDS SOCIETY
dc.journal.volume25
dc.titleThirdline antiretroviral therapy including raltegravir RAL darunavir DRVr andor etravirine ETR is well tolerated and achieves durable virologic suppression over 144 weeks in resourcelimited settings ACTG A5288 strategy trial
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Journal.pdf
Size:
409.54 KB
Format:
Adobe Portable Document Format
Description:
Journal
Download
Collections
Research Outputs (Clinical Medicine)